NBC Today Anchor Marc Fein: I had the honor of talking to DMN Dallas City Columnist Robert Wilonsky today about his battle with cancer. He was told he wouldn’t see his son’s next birthday. He did, and his story is remarkable.
Robert Wilonsky, City Columnist Last summer, my doctor told me I would probably be dead before my son went to college. At
Daniel George, MD; Toni Choueiri, MD; Walter Stadler, MD; and Richard W. Joseph, MD, discuss data from the CABOSUN trial and the expanded FDA approval for cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma.
The first NHS cancer patient to benefit from a breakthrough procedure that primes the body’s immune system to ‘seek and destroy’ tumour cells has stunned doctors with his recovery after being given just weeks to live.
American Cancer Society Current Grants by Cancer Type Current as of March 1, 2018 Cancer Type Number of Grants involving Cancer Type**
CLICK HERE TO VIEW THE VIDEO
Adi Diab, MD, discusses the synergistic mechanisms of NKTR-214 and nivolumab and the promising results of the phase I/II PIVOT-02 trial evaluating the use of NKTR-214 combined with nivolumab in multiple solid tumor types.
The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma (RCC).
Pembrolizumab monotherapy in the first-line setting induced a response among nearly 40% of patients with clear cell renal cell carcinoma across all IMDC risk groups, according to interim results from cohort A of the KEYNOTE-427 trial presented at the ASCO Annual Meeting.